A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mesoblast
- 12 Oct 2016 Status changed from active, no longer recruiting to completed.
- 17 Mar 2016 Results of this trial were published in Diabetes Care, according to a Mesoblast media release.
- 09 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.